What were the results of the COMPANION trial of implantable cardioverter-defibrillator (ICD) therapy?

Updated: Feb 13, 2017
  • Author: Daniel M Beyerbach, MD, PhD; Chief Editor: Jeffrey N Rottman, MD  more...
  • Print
Answer

Answer

In the COMPANION trial, pacemakers and, to an even greater extent, ICDs, were found to reduce the risk of death in patients with advanced heart failure, even when there was no indication for pacemaker or ICD treatment.

In the COMPANION trial, patients with advanced heart failure, NYHA functional class III or IV, an LVEF of 35% or less, and intraventricular conduction delay with QRS duration of over 120 milliseconds, but with no indication for pacemaker or ICD implant, were randomized to optimal medical therapy alone or in combination with cardiac resynchronization therapy with either a biventricular pacemaker or biventricular pacemaker-defibrillator.

Risk of hospitalization or death from heart failure was reduced by 34% in the pacemaker group and by 40% in the defibrillator group. Risk of death from any cause was reduced by 24% in the pacemaker group and by 36% in the defibrillator group. [20]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!